By CERBIOS-PHARMA SA
To get in touch with Cerbios announces key management changes, simply fill out the form below.
Subscribe to Supplier
Cerbios announces key management changes
Lugano, Switzerland: – High-tech CDMO Cerbios-Pharma SA (Cerbios) has announced key changes to its leadership with a new Chief Commercial Officer and Director of Quality Assurance.
Mr. Denis Angioletti replaces Mr. Andrea Tam as Chief Commercial Officer (CCO) while Ms. Francesca Nembri takes over the role of QA/DRA Director and Qualified Person under European Union pharmaceutical regulations.
Cerbios CEO, Dr. Gabriel Haering, commented:
“Denis Angioletti, as new CCO and Francesca Nembri, as QA are both excellent additions to our team with their strong experience and competences gained in different companies.”
“We welcome additional know-how and different points-of-view as constantly delivering value to Cerbios in our 40th Anniversary year,” the CEO added.
Moves within Chemholding
Former CCO Andrea Tam has been promoted to CEO of a Cerbios’ sister company and Clarissa Gobetti (former QP) has also moved to the same company as Scientific Affairs Director.
“Both Andrea and Clarissa have really done an excellent job for Cerbios’ change and growth. Fortunately, they remain within the Chemholding group of companies and are available to support ongoing Cerbios’ activities and partners if required,” says Dr. Gabriel Haering.
“On the one hand it was not easy to let them leave Cerbios for this new venture, but on the other, it was such an opportunity for a new step in their career. I wish both of them great success: they deserve it,” said Dr. Haering.
Cerbios-Pharma SA is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners worldwide. Cerbios specializes in the development and production of high potency active pharmaceutical ingredients (HPAPIs) in the area of fine chemicals and biologicals.
Cerbios Chemical Division offers exclusive, third party manufacturing services for HPAIs while Biological Division produces monoclonal antibodies, recombinant proteins and pharma probiotics.
Cerbios provides full CMC support to its worldwide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
Since 2015, Cerbios has been a member of the ADC manufacture PROVEO™ consortium, forged with CMC Biologics of Denmark, together with Germany’s Oncotec and IDT Biologika. PROVEO can offer a one-stop shop service from substance development through to full finish.